Therapy treats patients with specific types of ovarian, fallopian tube or primary peritoneal cancer
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s Lynparza.
The therapy, also known as olaparib, is indicated for the maintenance treatment of BRCA-mutated relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer.
It specifically treats patients who have already had two or more courses of platinum-based chemotherapy…
